Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis-Reference-Cited by-同舟云学术

Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis

Published:2017-04-05 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Giampieri Riccardo,Prete Michela del,Prochilo Tiziana,Puzzoni Marco,Pusceddu Valeria,Pani Fabiana,Maccaroni Elena,Mascia Roberta,Baleani Maria Giuditta,Meletani Tania,Berardi Rossana,Lanzillo Anna Maria,Mariotti Stefano,Zaniboni Alberto,Cascinu Stefano,Scartozzi Mario

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep45703.pdf

Reference26 articles.

1. Wilhelm, S. M. et al. Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 129, 245–55 (2011).

2. Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 381, 303–12 (2013).

3. Li, J. et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 16, 619–29 (2015).

4. Tougeron, D . et al. REBECCA: a large cohort study of regorafenib (REG) in the real-life setting in patients (pts) previously treated for metastatic colorectal cancer (mCRC). Ann Oncol. 25, iv 167–09 (2014).

5. Van Cutsem, E. et al. LBA-05 results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer. Ann Oncol. 26, iv 118 (2015).

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine-related adverse conditions induced by tyrosine kinase inhibitors;Annales d'Endocrinologie;2023-05

2. Assessing the Future of Solid Tumor Immunotherapy;Biomedicines;2022-03-11

3. Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study;Clinical Colorectal Cancer;2021-12

4. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study;Journal of Clinical Oncology;2021-10-01

5. Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors;The Oncologist;2021-01-05